Immunity enhancing agent for cancer by allergin-1 antagonist

Abstract

A method for suppression of progress of, suppression of recurrence of and/or treatment of cancer includes administering an Allergin-1 antagonist in a therapy of a cancer patient with insufficient therapeutic efficacy by a tumor immunotherapeutic agent, or a cancer therapy in combination with an anti-cancer drug.

1 . A method for enhancing an immunity against cancer in a cancer patient, comprising administering an effective dosage of an anti-Allergin-1 antibody to the patient. 
     
     
         2 . The method according to  claim 1 , wherein the anti-Allergin-1 antibody suppresses immunosuppressive intracellular signaling of Allergin-1. 
     
     
         3 . The method according to  claim 1 , wherein the anti-Allergin-1 antibody suppresses progress of, suppresses recurrence of and/or treats cancer. 
     
     
         4 . The method according to  claim 1 , wherein the anti-Allergin-1 antibody is an anti-human Allergin-1 antibody. 
     
     
         5 . The method according to  claim 1 , wherein the anti-Allergin-1 antibody is a monoclonal antibody. 
     
     
         6 . The method according to  claim 5 , wherein the anti-Allergin-1 monoclonal antibody is of IgG 1  or IgG 4  isotype. 
     
     
         7 . The method according to  claim 5 , wherein the anti-Allergin-1 monoclonal antibody is an antibody fragment selected from the group consisting of Fab, Fab′, Fv, scFv and (Fab′) 2  fragments. 
     
     
         8 . The method according to  claim 5 , wherein the anti-Allergin-1 monoclonal antibody is a humanized or human antibody. 
     
     
         9 . The method according to  claim 5 , wherein the anti-Allergin-1 monoclonal antibody is a humanized or human anti-human Allergin-1 monoclonal IgG 1  or IgG 4  antibody. 
     
     
         10 . The method according to  claim 1 , wherein the anti-Allergin-1 antibody is an Allergin-1 multi-specific antibody recognizing two or more different epitopes presented on one Allergin-1 molecule. 
     
     
         11 . The method according to  claim 1 , wherein the cancer is solid cancer or hematologic cancer. 
     
     
         12 . The method according to  claim 11 , wherein the solid cancer is one or more selected from malignant melanoma, non-small cell lung cancer, small cell lung cancer, head and neck cancer, renal cell cancer, clear cell renal cell cancer, breast cancer, ovarian cancer, ovarian clear cell adenocarcinoma, bone and soft tissue sarcoma, glioblastoma, gliosarcoma, nasopharyngeal cancer, uterine cancer, anal cancer, colorectal cancer, hepatocellular cancer, esophageal cancer, pancreatic cancer, stomach cancer, urothelial cancer, prostate cancer, fallopian tube cancer, primary peritoneal cancer, pleural mesothelioma and myeloproliferative syndrome. 
     
     
         13 . The method according to  claim 11 , wherein the hematologic cancer is one or more selected from multiple myeloma, non-Hodgkin lymphoma, Hodgkin lymphoma, acute myeloid leukemia and chronic myeloid leukemia. 
     
     
         14 . The method according to  claim 1 , wherein the anti-Allergin-1 antibody is administered to a cancer patient; wherein the cancer patient is being treated or has been treated with an anticancer drug; and wherein the anticancer drug has insufficient therapeutic efficacy in said patient. 
     
     
         15 . The method according to  claim 14 , wherein the anti-cancer drug is a tumor immunotherapeutic agent. 
     
     
         16 . The method according to  claim 15 , wherein the tumor immunotherapeutic agent is one or more selected from an anti-PD-1 antibody, an anti-PD-L1 antibody, an anti-CTLA-4 antibody, an anti-LAG-3 antibody, an anti-Tim3 antibody or an anti-TIGIT antibody. 
     
     
         17 . The method according to  claim 1 , wherein the anti-Allergin-1 antibody is administered to a cancer patient in combination with the one or more anti-cancer drugs. 
     
     
         18 . The method according to  claim 17 , wherein the anti-Allergin-1 antibody and the anti-cancer drug are in different preparations. 
     
     
         19 . The method according to  claim 17 , wherein the anti-Allergin-1 antibody and the anti-cancer drug are in one preparation. 
     
     
         20 . The method according to  claim 17 , wherein the anti-cancer drug is a tumor immunotherapeutic agent. 
     
     
         21 . The method according to  claim 20 , wherein the tumor immunotherapeutic agent is one or more selected from an anti-PD-1 antibody, an anti-PD-L1 antibody, an anti-PD-L2 antibody, a PD-L1 fusion protein, a PD-L2 fusion protein, an anti-CTLA-4 antibody, an anti-LAG-3 antibody, an anti-Tim3 antibody, an anti-KIR antibody, an anti-BTLA antibody, an anti-TIGIT antibody, an anti-VISTA antibody, an anti-CD137 antibody, an anti-OX40 antibody, an anti-HVEM antibody, an anti-CD27 antibody, an anti-GITR antibody, an anti-CD28 antibody, an anti-CCR4 antibody and an anti-CD4 antibody. 
     
     
         22 . The method according to  claim 21 , wherein the anti-PD-1 antibody is Nivolumab, REGN-2810, Pembrolizumab, PDR-001, BGB-A317, STI-A1110 or AMP-514. 
     
     
         23 . The method according to  claim 21 , wherein the anti-PD-L1 antibody is Atezolizumab, Avelumab or Durvalumab. 
     
     
         24 . The method according to  claim 21 , wherein the anti-CTLA-4 antibody is Ipilimumab or Tremelimumab. 
     
     
         25 . The method according to  claim 21 , wherein the PD-L2 fusion protein is AMP-224.